BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 29771256)

  • 1. Rheumatoid arthritis: new monoclonal antibodies.
    Serio I; Tovoli F
    Drugs Today (Barc); 2018 Mar; 54(3):219-230. PubMed ID: 29771256
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Profile of sarilumab and its potential in the treatment of rheumatoid arthritis.
    Raimondo MG; Biggioggero M; Crotti C; Becciolini A; Favalli EG
    Drug Des Devel Ther; 2017; 11():1593-1603. PubMed ID: 28579757
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacodynamic biomarkers and differential effects of TNF- and GM-CSF-targeting biologics in rheumatoid arthritis.
    Guo X; Wang S; Godwood A; Close D; Ryan PC; Roskos LK; White WI
    Int J Rheum Dis; 2019 Apr; 22(4):646-653. PubMed ID: 30358109
    [TBL] [Abstract][Full Text] [Related]  

  • 4. IL-6 inhibitors for treatment of rheumatoid arthritis: past, present, and future.
    Kim GW; Lee NR; Pi RH; Lim YS; Lee YM; Lee JM; Jeong HS; Chung SH
    Arch Pharm Res; 2015; 38(5):575-84. PubMed ID: 25648633
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Emerging biologic drugs for the treatment of rheumatoid arthritis.
    Puppo F; Murdaca G; Ghio M; Indiveri F
    Autoimmun Rev; 2005 Nov; 4(8):537-41. PubMed ID: 16214092
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tocilizumab in the treatment of rheumatoid arthritis: an evidence-based review and patient selection.
    Biggioggero M; Crotti C; Becciolini A; Favalli EG
    Drug Des Devel Ther; 2019; 13():57-70. PubMed ID: 30587928
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New therapies in the management of rheumatoid arthritis.
    Buch MH; Emery P
    Curr Opin Rheumatol; 2011 May; 23(3):245-51. PubMed ID: 21427579
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting GM-CSF in rheumatoid arthritis.
    Avci AB; Feist E; Burmester GR
    Clin Exp Rheumatol; 2016; 34(4 Suppl 98):39-44. PubMed ID: 27586802
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Etanercept for the treatment of rheumatoid arthritis.
    Zhao S; Mysler E; Moots RJ
    Immunotherapy; 2018 Mar; 10(6):433-445. PubMed ID: 29482402
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk of herpes zoster in patients with rheumatoid arthritis treated with anti-TNF-alpha agents.
    Strangfeld A; Listing J; Herzer P; Liebhaber A; Rockwitz K; Richter C; Zink A
    JAMA; 2009 Feb; 301(7):737-44. PubMed ID: 19224750
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of sirukumab in patients with active rheumatoid arthritis refractory to anti-TNF therapy (SIRROUND-T): a randomised, double-blind, placebo-controlled, parallel-group, multinational, phase 3 study.
    Aletaha D; Bingham CO; Tanaka Y; Agarwal P; Kurrasch R; Tak PP; Popik S
    Lancet; 2017 Mar; 389(10075):1206-1217. PubMed ID: 28215362
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase II randomized study of subcutaneous ixekizumab, an anti-interleukin-17 monoclonal antibody, in rheumatoid arthritis patients who were naive to biologic agents or had an inadequate response to tumor necrosis factor inhibitors.
    Genovese MC; Greenwald M; Cho CS; Berman A; Jin L; Cameron GS; Benichou O; Xie L; Braun D; Berclaz PY; Banerjee S
    Arthritis Rheumatol; 2014 Jul; 66(7):1693-704. PubMed ID: 24623718
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Room for more IL-6 blockade? Sarilumab for the treatment of rheumatoid arthritis.
    June RR; Olsen NJ
    Expert Opin Biol Ther; 2016 Oct; 16(10):1303-9. PubMed ID: 27464017
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Secukinumab for rheumatology: development and its potential place in therapy.
    Koenders MI; van den Berg WB
    Drug Des Devel Ther; 2016; 10():2069-80. PubMed ID: 27445458
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biologic agents for rheumatoid arthritis: 2008 and beyond.
    Sweiss NJ; Hushaw LL
    J Infus Nurs; 2009; 32(1 Suppl):S4-17; quiz S19-24. PubMed ID: 19142153
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeted therapy in rheumatoid arthritis.
    Köller MD
    Wien Med Wochenschr; 2006 Jan; 156(1-2):53-60. PubMed ID: 16465614
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [New approaches to pharmacotherapy for rheumatoid arthritis: perspective for use of tocilizumab (monoclonal antibodies to interleukin-6 receptor)].
    Nasonov EL
    Ter Arkh; 2010; 82(5):64-71. PubMed ID: 20597275
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Fully human anti TNF-alpha monoclonal antibodies (adalimumab, golimumab)].
    Hirohata S
    Nihon Rinsho; 2007 Jul; 65(7):1202-8. PubMed ID: 17642233
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumor necrosis factor (TNF) inhibitor therapy for rheumatoid arthritis.
    Segal B; Rhodus NL; Patel K
    Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2008 Dec; 106(6):778-87. PubMed ID: 18930662
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mavrilimumab: a unique insight and update on the current status in the treatment of rheumatoid arthritis.
    Crotti C; Biggioggero M; Becciolini A; Agape E; Favalli EG
    Expert Opin Investig Drugs; 2019 Jul; 28(7):573-581. PubMed ID: 31208237
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 13.